Memorable trades executed with commentaries for this week.
November 18, 2024 to November 22, 2024
For this week an initial hypothetical investment of $10,000 yielded $83.273 (that's right -- $83,273) in net gains from the companies of our memorable trades. Naturally, the fully documented results as stated may not represent future transactions, but if history is the judge, our G-101-SPM AI algorithm is the the best there is. Indeed, to make BIG MONEY in the stock market YOU NEED TO BE FASTER THAN A SPEEDING RABBIT WHO KNOWNS WERE TO GO.
PART ONE
11.22.24
$CRNC $7.35 bid. SELL/TAKE PROFIT ON 50% OF LONG POSITION TO COVER ORIGINAL COST).
note: Original cost $3.16 (6.5.24). DAC (dollar average cost including partial sale reduces investment cost on 10,000 shares to $ -1.13.)
CHANGE EXIT ON 50% BALANCE TO $12.00 FROM $7.00 (long term).
11.22.24
$APLD $9.16 bid. DAC (dollar average cost) $6.81 (11.15.24).
CHANGE EXIT TO $14.00 FROM $10.00 on improved SPM tag.
11.21.24
$CEVA $28.72 bid. SELL/TAKE PROFITS
DAC (dollar average cost) $23.935 (11.5.24).
11.21.24
$QUBT $4.78 +1.10 bid. DAC (dollar average cost) $1.39 (11.13.24). EXIT $8.00.
note: Unusually active option classes created imbalance/ beginning to create short squeeze.
11.21.24
$NNE $28.81 +5.74 bid. DAC (dollar average cost) $20.64 (10.30.24). * EXIT $45.00 --Legacy Holding status.
BRIEF: Today announced that the Hon. John G. Vonglis, former Chief Financial Officer of the U.S. Department of Energy (DOE), Acting Director of DOE's Advanced Research Projects Agency-Energy (APRA-E), and Chairman of NANO Nuclear's Executive Advisory Board for Strategic Initiatives has transitioned to an active corporate role within NANO Nuclear as its Executive Director of Global Government Affairs.
note: His appointment is a key element in NANO Nuclear's management expansion strategy, which has attracted top financial, regulatory, and scientific leaders to NANO Nuclear in recent months. The assembled team of highly qualified and proven leaders positions NANO Nuclear to capitalize on the rising momentum in the industry, fueled by U.S. government support, growing public interest, and favorable capital market conditions.
* Click SEARCH icon on our landing page to review the postings
11.21.24
$CRNC $4.81 +2.02 bid. DAC (dollar average cost) $3.16 (6.5.24). EXIT $7.00.
BRIEF: Today reported its fourth quarter and fiscal year 2024 results for the year ended September 30, 2024.
^ Q4 Revenue exceeds high end of guidance; positive cash flow from operations of $6.1 million
^ Transformation plan on track to deliver net annualized cost savings of $35-$40 million
^ Initial FY25 revenue guidance of $236 to $247 million
^ Record high of 22 platform launches in FY24, including 6 for generative AI solutions and 4 in Q4.
11.21.24
$AMLX $5.29 DAC (dollar average cost) $1.86 (8.12.25). EXIT $10.00
BRIEF: - Goldman analyst Corinne Jenkins highlighted, "AMLX recently acquired GLP-1R antagonist avexitide from Eiger BioPharmaceuticals.
note: The agent is expected to begin a pivotal Ph3 study in post-bariatric hypoglycemia (PBH) in 1Q25, with topline data expected in 2026, and has become a key driver of the investment thesis for AMLX, per our conversations. Data to-date is largely supportive of the agent demonstrating a clinical benefit for patients with PBH. Based on our review of the prevalent market of PBH coupled with conversations with physicians, we see a significant addressable market for new agents, and estimate peak sales for avexitide at $1B (PoS: 50%)."
11.20.24
$SMCI $25.38 bid. SELL/TAKE PROFIT.
DAC (dollar average cost) $22.17 (11.12.24).
Plan to REVISIT.
11.20.24
$QUBT $2.77 bid. DAC (dollar average cost) $1.39 (11.13.24). EXIT $8.00.
BRIEF: Quantum Computing announces that the Company has received its second purchase order for its thin film lithium niobate photonic chip foundry from the University of Texas at Austin.
note: The order will support the research efforts of the University's RF Acoustic Microsystem Group and is part of the QCi Foundry's pilot launch program, with fulfillment expected in Q1 2025.
11.20.24
* CORRECTION AS TO PRIOR DATE BUY.
$NAMS $18.50 ask. BUY/ADD TO LONG POSITION carries SPM 88.01 tag to $45.00 in midterm
DAC (dollar average cost) (2) $17.675 last $16.85 (8.27.24).
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
$NAMS $18.50 ask. BUY/ADD TO LONG POSITION carries SPM 88.01 tag to $45.00 in midterm
DAC (dollar average cost) (2) $17.675 last $16.85 (8.37.24).
11.20.24
$NAMS $23.68 last bid (halted)
DAC (dollar average cost) $16.85 (8.27.24).
NOTE: REMOVE EXIT at $27.00/MAINTAIN LEGACY HOLDING STATUS.
NEW EXIT WILL BE DETERMINED.
UPDATE:
NewAmsterdam Pharma announces "positive" topline data from the Company’s Phase 3 TANDEM clinical trial.
^Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg monotherapy at day 84 with statistical significance (p<0.001).
^Obicetrapib and ezetimibe fixed-dose combination observed to lower LDL-C by approximately 50% at day 84, compared to placebo, with over 70% of patients achieving LDL-C levels below 55 mg/dL.
^Data supports global regulatory filings of the obicetrapib 10 mg and ezetimibe 10 mg fixed-dose combination.
^Observed to be well tolerated with safety results in line with prior studies.
^^^ NewAmsterdam to host conference call today at 8:00 a.m. ET.
11.19.24
$NVDL $79.26 bid. SELL/TAKE PROFIT.
DAC (dollar average cost) $74.92 (11.15.24).
PLAN TO REVISIT.
11.19.24
$ACRS $4.14. DAC (dollar average cost) $1.49). EXIT $7.00.
RETAIN POSITION.
From the other side: Leerink Partners analyst Thomas J. Smith added, "We are upgrading ACRS to Outperform (from Market Perform) and raising our PT to $7 (vs. $2 prior), representing >120% upside from current levels. Following completion of their strategic review, we expect investor focus to shift to ACRS' newly strengthened immunology focused pipeline that includes two in-licensed biologics from discovery-focused Biosion (private) -- BSI-045B and BSI-502. Signaling further confidence, the company announced a concurrent and oversubscribed $80mn private placement to support their newly bolstered pipeline and operational efforts. We believe these updates have ushered in a new chapter for ACRS, bringing a renewed strategic vision for the company and an attractive catalyst path over the next ~6-12 months which has the potential to further derisk BSI-045B and unlock meaningful fundamental value."
$ACRS $3.67 +0.51. DAC (dollar average cost) $1.48 (10.1.24).
CHANGE EXIT TO $7.00 FROM $4.00.
BRIEF: BTIG analyst Julian Harrison upgrades Aclaris Therapeutics(ACRS) from Neutral to Buy and announces $8 price target.
11.19.24
$SMCI $28.56 + $7.02. DAC (dollar average cost) $22.17 (11.12.24)
CHANGE EXIT TO $35.00 from $24.50.
As posted three times. in essence, "... once new audit is announced watch for a 25% jump."
Super Micro Computer Inc. shares jumped as much as 42% in premarket trading after the company hired a new auditor and filed a plan to come into compliance with Nasdaq listing requirements.
11.18.24
$CPRX $20.12 bid.* DAC (dollar average cost includes partial sale of position to reduce cost to $12.36). EXIT $27.00.
BRIEF: Catalyst Pharma initiated with an Overweight at Stephens; tgt $35.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
11.18.24
11.18.24
$ACRS $3.14 bid. DAC (dollar average cost) $1.48 (7.17.24). EXIT $4.00.
BRIEF: Aclaris Therapeutics upgraded to Overweight from Neutral at Piper Sandler; tgt raised to $13
$ACRS $2.20 bid. DAC (dollar average cost) $1.48 (7.17.24.)
CHANGE EXIT TO $4.00 FROM $3.00.
UPDATE: Co announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of 35,555,555 shares of common stock at a purchase price of $2.25 per share, for gross proceeds of approximately $80.0 million.
The private placement is expected to close on or about November 19, 2024, subject to the satisfaction of customary closing conditions.
Co also announced that it has entered into an exclusive license agreement with Biosion, Inc. (Biosion) for worldwide rights to BSI-045B, a potential best-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-clinical stage, novel bispecific antibody that is directed against both TSLP and IL4R.
11.18.24
$CAPR $18.71 bid. DAC (dollar average cost includes partial sale of *position to reduce cost to zero). EXIT $35.00.
BRIEF: Capricor Therapeutics (CAPR) initiated with a Buy at JonesResearch.
* Original pick $3.91 (8.2.24).
** Click SEARCH (magnifying glass) icon on our landing page to review the postings.
11.18.24
$AMLX $5.01 bid. DAC (dollar average cost) $1.86 (8.12.24). EXIT $10.00.
UPDATE: Amylyx Pharmaceuticals (AMLX) upgraded to Outperform from Neutral at Robert W. Baird; tgt raised to $11
11.18.24
$RGNX $11.19 +1.56 bid. DAC (dollar average cost) (6) 10.45 last $9.52 (11.15.24). EXIT $14.99.
BRIEF: today announced that AFFINITY DUCHENNE®, the multi-center, open-label trial of RGX-202, a potential best-in-class gene therapy for Duchenne muscular dystrophy (Duchenne), has advanced to pivotal stage and dosed its first patient. The company also announced new, positive efficacy and safety data from the Phase I/II portion of the study, including the first functional data.
"The initiation of our pivotal trial and newly released positive functional data are exciting milestones on our path to rapidly deliver RGX-202, the only next generation gene therapy in pivotal phase, to the Duchenne community," said Curran M. Simpson President and Chief Executive Officer of REGENXBIO (RGNX).
11.18.24
$CYBN $12.76 +1.16 bid. DAC (dollar average cost) $9.37 (10.1.24). EXIT $15.00
UPDATE: Today announced unprecedented 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated psilocin program in development for the potential adjunctive treatment of major depressive disorder (“MDD”). As previously announced, CYB003 received Breakthrough Therapy Designation by the U.S Food and Drug Administration (the “FDA”) for this indication, which provides an expedited review pathway.
PART TWO
Our AI algorithm is an investment predictor that gathers data from 129 preset sources and presents the values as a SPM matrix number. The database tracks over 5215 individual stocks with each one carrying a "floating" SPM tag. The higher the value the greater the subjective probability of the collective data being accurate, and culminating with the issuance of an auxiliary SPM tag.
^Follow the daily abstracts: SPMNOTES, FIRSTLOOK, OPTIONACTION, INSIDERS, DILUTION, SHOWTIME, NOISE, FLASHTRADE, QUESTIONBOX and SURVEY.
^DAC means “dollar average cost” and determines the true cost of the investment position during the cycle of the trade.
IDEA: Devote quality time to understand how to apply the data as a "positional investor."
* Click https://stocktwits.com/G101SPM SEARCH on (magnifying glass) icon on our landing page to review the postings.
MISSION STATEMENT: To prove that non-human intervention by an analytical chatbot is far superior than the other kind. The rise of generative AI (GenAI) models, like OpenAI’s GPT, has accelerated our transformation. These tools do more than process data, G-101 SPM AI generates meaningful content, automate workflows, and unlock insights in ways traditional AI could never achieve.
ARE YOU READY TO MAKE BIG MONEY IN THE STOCK MARKET?
Comments